Credits: Canva
After mpox outbreak, Africa is under the threat of yet another virus outbreak, this is the Marburg virus outbreak in Rwanda. So far, six people have died from the outbreak, confirmed the health minister. Most victims were the healthcare workers in the hospital's intensive care unit. As per reports, 20 cases have been identified since the outbreak was confirmed on Friday.
With the fatality rate of 8% it is the same virus family as Ebola. The main carrier is from fruit bats which spreads to humans then through the contact of bodily fluids of infected individuals, it spreads to others.
The common signs and symptoms of the Marburg virus include fever, pain, diarrhoea, vomiting and in the case of extreme blood loss, death too can happen.
So far, there is no specific treatment or vaccine for the virus. However, treatments like drugs and immune therapy are being developed as per the World Health Organisation (WHO).
Rwanda says that it has intensified its contact tracing, surveillance and testing to contain the spread. It has also tracked about 300 people who had come into contact with individuals affected by the Marburg virus.
The health minister has urged people to stay vigilant and avoid any physical contact and to wash their hands with clean water, soap or sanitiser and report any suspected case.
As of now, most of the cases have spread to the capital in Kigali. In light of this, the US Embassy in the city has advised its employees to work remotely for the next week.
This is the first time Rwanda has confirmed for Marburg cases, before this, in 2023, Tanzania confirmed the outbreak, whereas three people had died of this in Uganda in 2017.
As per WHO, this virus kills half of the people it infects. In the previous outbreaks, it has killed between 24% to 88% of the patients.
The virus was first detected in 1976 after 31 people were infected, out of which 7 died in simultaneous outbreak in Marburg and Frankfurt in Germany, and Belgrade in Serbia.
The source was traced to African green monkeys who were imported from Uganda. However, other animals too are linked to the virus spread, including bats.
In the past, the virus outbreaks have happened in countries like Equatorial Guinea, Ghana, the Democratic Republic of the Congo, Kenya, South Africa, Uganda, and Zimbabwe. In 2005, this virus killed 300 people in Angola.
However, for the rest of the world, only two people have died from the virus in the rest of the world, with one of them being in Europe, and the other in the US. These both have been on expeditions to caves in Uganda.
Credit: iStock
The US Centers for Disease Control and Prevention (CDC) has reported elevated activity of multiple respiratory viruses across the country during the 2026–27 winter season, including rhinovirus/enterovirus and respiratory adenovirus.
While respiratory adenovirus infections are increasing in some regions, the agency says the trends are expected.
In its latest update, the CDC also highlighted Group A strep infections, whooping cough and Mycoplasma pneumoniae, the bacteria responsible for walking pneumonia, as other respiratory illnesses circulating in the US.
Rhinovirus/enterovirus and respiratory adenovirus activity are elevated nationally, according to the CDC. Respiratory adenovirus infections are also increasing in some parts of the country.
Both viruses can cause respiratory symptoms such as cough, fever, nasal congestion and shortness of breath. In severe cases, infections may progress to bronchitis or pneumonia.
Rhinoviruses are among the common causes of the common cold and can also trigger asthma attacks. People with asthma, weakened immune systems or other underlying medical conditions may be at higher risk of severe illness.
Respiratory adenoviruses typically cause mild cold- or flu-like symptoms but can also lead to bronchitis, pneumonia, conjunctivitis (pink eye) and gastrointestinal illness. People with weakened immune systems or existing respiratory or cardiac conditions are at greater risk of severe disease. There are no vaccines available to the public for these infections.
Reports of Group A strep infections increased in the US as children returned to school this fall, before stabilising, the CDC said.
Most reported infections have involved strep throat or scarlet fever.
However, the bacteria can also cause serious conditions, including streptococcal toxic shock syndrome and necrotising fasciitis, commonly known as flesh-eating disease.
Although most infections are minor, serious illness can occur, particularly among older adults and people with certain underlying health conditions. Healthcare providers can diagnose the infection through testing and prescribe antibiotics when needed.
Respiratory infections caused by Mycoplasma pneumoniae remain low in most parts of the US, based on emergency department visits and positive test results.
The bacteria commonly cause tracheobronchitis, often described as chest colds, but can also lead to walking pneumonia. People of all ages can get infected, although school-aged children and young adults are most commonly affected.
Most mild infections resolve without medication, while healthcare providers may prescribe antibiotics for pneumonia.
Whooping cough, or pertussis, continues to circulate at lower levels compared with post-pandemic peaks, according to the CDC.
The highly contagious respiratory infection is caused by the bacterium Bordetella pertussis and can spread easily from person to person.
Babies younger than one year are at the highest risk of severe disease and complications. Vaccination is the best way to prevent complications, and healthcare providers generally treat the infection with antibiotics.
The CDC recommends basic precautions to reduce the spread of respiratory viruses and bacteria, including:
Credit: iStock
An estimated 370,000 people developed rifampicin-resistant tuberculosis (RR-TB) worldwide in 2025, highlighting the continuing threat of drug-resistant TB, according to the World Health Organization (WHO).
The Global Tuberculosis Report 2026 showed a gradual decline in RR-TB since 2015. However, major gaps in diagnosis and treatment persist.
Only 155,333 people were diagnosed with RR-TB and started treatment in 2025, just 42% of the estimated number who developed the disease.
Drug-resistant TB occurs when bacteria become resistant to one or more medicines. Rifampicin resistance is particularly concerning because rifampicin is a key first-line TB drug.
Also read: Global TB Deaths Fall 35% Since 2015, But 2030 Target Remains Distant: WHO
The proportion of new TB cases involving rifampicin resistance fell from 4.4% in 2015 to 3.1% in 2025.
Resistance remained higher among previously treated patients: 14.8% had RR-TB in 2025, down from 20% in 2015.
China, India, the Philippines and the Russian Federation together accounted for more than half of estimated global RR-TB cases in 2025.
Eastern Europe and Central Asia reported the highest proportions of RR-TB among previously treated patients, exceeding 50%.
India was also among five countries — alongside China, Indonesia, Pakistan and the Philippines — that accounted for about 60% of the global gap between estimated RR-TB cases and people enrolled on treatment.
Rifampicin-resistant TB is listed in WHO's Bacterial Priority Pathogens List under the critical group.
WHO identifies two main drivers of multidrug- and rifampicin-resistant TB (MDR/RR-TB): inappropriate treatment and person-to-person transmission.
Incorrect use of TB medicines, poor-quality formulations, improper storage and premature treatment stoppage can contribute to drug resistance.
Resistant bacteria can also spread between people. Those with pulmonary TB can transmit the infection through coughing, sneezing or talking. Others become infected by inhaling airborne bacteria.
Timely diagnosis, appropriate treatment and infection prevention are particularly important in crowded settings such as hospitals and prisons.
Read More: 15 Lakh Asymptomatic TB Cases Detected In India: How TB Mukt Bharat Abhiyaan Is Driving Screening
The treatment success rate for RR-TB reached 70% among patients who started treatment in 2023, the latest year with available outcome data.
This was below the 71% recorded in 2022 but above the rates in 2021 (68%), 2020 (64%) and 2012 (50%).
By comparison, treatment success for drug-susceptible TB is about 90%, according to WHO.
Across WHO regions, RR-TB treatment success ranged from 56% in the Region of the Americas to 77% in the African Region.
WHO recommends all-oral regimens for drug-resistant TB, including shorter courses for eligible patients. Six-month regimens accounted for 42% of RR-TB treatment in 2025, up from 18% in 2024 and 3% in 2023.
By the end of 2025, 106 countries were using these regimens, compared with 98 in 2024 and 60 in 2023.
They were the most frequently used treatment option in five of the six WHO regions. Uptake was highest in the Eastern Mediterranean (72%) and African (65%) regions.
Europe was the only region where longer regimens remained the main option for a large share of patients (76%).
WHO recommends the six-month BPaLM regimen — bedaquiline, pretomanid, linezolid and moxifloxacin — for eligible patients with MDR/RR-TB.
Treatment choices depend on drug resistance, previous exposure to TB medicines and other clinical factors.
Expanding access to rapid drug-resistance testing, starting treatment promptly and preventing transmission remain key to tackling drug-resistant TB.
Credit: AI image
There are currently no proven treatments to reverse Alzheimer’s but researchers are actively looking into treatments and therapies that could decrease the pace of disease progression and cognitive decline.
An experimental drug may be on the path to achieve that goal after it was able to slow cognitive decline by 38% over two years in people with early-stage Alzheimer’s. The development came to light after new clinical trial findings were announced by pharmaceutical company Biogen.
The experimental drug that targets a protein linked to Alzheimer's disease is called diranersen (BIIB080). It is equipped to reduce levels of tau, a protein that accumulates abnormally in the brains of people with Alzheimer's disease and causes damage to nerve cells.
Results from the Phase 2 CELIA trial, presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference, showed that patients receiving the lowest dose of diranersen experienced more cognitive decline at two years than was reported at the 18-month assessment.
The 60 mg dose, administered through an injection into the fluid surrounding the spinal cord twice a year, slowed cognitive decline by 38% on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale at 96 weeks. This was an improvement from the 26% slowing that was observed at 76 weeks.
The two-year results corresponded to a 1.09-point difference on the CDR-SB scale compared to the control group. The scale measures changes in memory, thinking abilities and the ability to do everyday activities.
Tau is a protein that normally helps maintain the structure and stability of nerve cells. But, in Alzheimer's disease, tau can become abnormal, clump together and form structures known as neurofibrillary tangles inside brain cells.
They interfere with the normal functioning of nerve cells and can lead to progressive brain damage, memory loss and cognitive decline, symptoms usually seen in Alzheimer’s patients.
Diranersen belongs to a class of medicines that work by targeting genetic messages involved in producing proteins. In this case, diranersen targets the messenger RNA (mRNA) produced by the MAPT gene, which carries instructions for making tau protein. By targeting this genetic message, the drug aims to reduce the production of tau at source.
Recently approved Alzheimer's treatments like lecanemab and donanemab target amyloid-beta plaques, another abnormal protein accumulation associated with the disease. They work by helping the body clear amyloid deposits from the brain and have demonstrated modest slowing of cognitive decline in people with early Alzheimer's.
Diranersen works differently by targeting tau production rather than amyloid accumulation.
Also read: Older Adults Receiving High-Dose Flu Shots Show Lower Alzheimer's Risk: Study
Biogen reported that diranersen was well tolerated over the two-year observation period as no new safety concerns came up.
Side effects mostly included headaches and back pain, which could have been due to lumbar puncture procedure used to administer the drug. A small number of participants also experienced confusion.
Unlike some existing Alzheimer's treatments, the trial did not report cases of amyloid-related brain swelling.
Diranersen is still undergoing clinical development and is not approved by the US Food and Drug Administration (FDA) or other regulatory authorities.
© $2026 Times Horizon Private Limited